Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Gene expression signature and the prediction of liver metastasis in colorectal cancer by DNA microarray


ABSTRACT: Samples were taken from colorectal cancers in surgically resected specimens in 189 colorectal cancer patients. The expression profiles were determined using Affymetrix Human Genome U133 Plus 2.0 arrays. Comparison between the sample groups allow to identify a set of discriminating genes that can be used for molecular markers for predicting liver metastasis. Keywords: repeat One hundred and eighty nine patients who underwent surgical resection of colorectal cancer were included in this study. Patients were evaluated at 3-month intervals for the first postoperative year and at 6-month intervals thereafter. Liver metastases were identified by clinical and laboratory examination, completed by liver ultrasound or CT scan. Patients were divided randomly into a training and a validation set. A training set consisted of 160 patients, while a test set 29 patients.

ORGANISM(S): Homo sapiens

SUBMITTER: Toshiaki Watanabe 

PROVIDER: E-GEOD-14095 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications

Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients.

Watanabe Toshiaki T   Kobunai Takashi T   Yamamoto Yoko Y   Matsuda Keiji K   Ishihara Soichiro S   Nozawa Keijiro K   Iinuma Hisae H   Konishi Tsuyoshi T   Horie Hisanaga H   Ikeuchi Hiroki H   Eshima Kiyoshi K   Muto Tetsuichiro T  

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 20110601 6


<h4>Purpose</h4>FOLFOX (a combination of leucovorin, fluorouracil and oxaliplatin) has achieved substantial success in the treatment of colorectal cancer (CRC) patients. However, about half of all patients show resistance to this regimen and some develop adverse symptoms such as neurotoxicity. In order to select patients who would benefit most from this therapy, we aimed to build a predictor for the response to FOLFOX using microarray gene expression profiles of primary CRC samples.<h4>Patients  ...[more]

Similar Datasets

2010-08-31 | E-GEOD-4459 | biostudies-arrayexpress
2010-08-31 | E-GEOD-4526 | biostudies-arrayexpress
2008-06-13 | E-GEOD-4554 | biostudies-arrayexpress
2013-01-03 | E-GEOD-19860 | biostudies-arrayexpress
2013-01-03 | E-GEOD-19862 | biostudies-arrayexpress
2012-11-29 | E-GEOD-34489 | biostudies-arrayexpress
2012-07-03 | E-GEOD-30540 | biostudies-arrayexpress
2009-01-16 | E-GEOD-13067 | biostudies-arrayexpress
2009-02-07 | E-GEOD-13294 | biostudies-arrayexpress
2014-01-14 | E-MTAB-1951 | biostudies-arrayexpress